Toggle menu

MAPP2 Study

Start date:
June 2018
End date:
December 2019
Co-ordinated by:
Rachel O'Brien
Main trial site:
Royal Infimary Edinburgh

The development of a new point of care test will detect miR-122 and allow point of care diagnosis of paracetamol toxicity with the aim of improved patient stratification on presentation to hospital and, therefore, improve patient care.

The aim of the study is to establish a biobank of human serum samples from patients with paracetamol overdose to develop and test the performance of our point of care test. This is a prospective, observational cohort study of participants aged 16 years or over presenting to the ED/AMU aiming to recruit 326 participants.

Chief Investigator

Dr James Dear

Consultant in Acute Medicine & Toxicology

Research Team

Rachel O'Brien

Lead Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Claire Cheyne

Senior Research Nurse

More EMERGE Trials

The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.

The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.  

This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.

Participants will be asked to return for 6 visits across 12 months to evaluate their health.

Across the UK the trial aims to recruit 10,260 volunteers.

If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh

Read more

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.

CERA

COVID-19 Emergency Response Assessment. A Professional Survey